THERAPY DOSSIER · th-548f31601bf0

SP600125

Drug · No confident ChEMBL match; JNK inhibitor (research tool)

Evidence & regulatory context

Mechanism: No confident ChEMBL match; JNK inhibitor (research tool)
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22015972 ↗2012Reported benefit

Effects of c-Jun N-terminal kinase signaling pathway on severe acute pancreatitis-associated lung injury.

RatChemical/toxinSprague-DawleyMalen = 72 rats in three groups (sham operation, severe acute pancr…

Model: Severe acute pancreatitis-associated lung injury induced by retrograde pancreatic duct injection of 5 percent sodium taurocholate

SP600125 reduced lung wet-to-dry weight ratio, myeloperoxidase activity, IL-1beta, TNF-alpha, ICAM-1 and phosphorylated JNK, and lowered lung injury scores relative to untreated severe acute pancreatitis.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…